Defining high-risk patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention: A comparison among different scoring systems and clinical definitions

Abstract Background Identification of high-risk patients with ST-segment elevation acute myocardial infarction (STEMI) is of the utmost importance for adequate patient stratification and evaluation of additive treatments. However, there is no consensus on the optimal definition of high-risk patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2012-05, Vol.157 (2), p.207-211
Hauptverfasser: Martinoni, Alessandro, De Servi, Stefano, Politi, Alessandro, Palmerini, Tullio, Musumeci, Giuseppe, Ettori, Federica, Zanini, Roberto, Piccaluga, Emanuela, Sangiorgi, Diego, Repetto, Alessandra, D'Urbano, Maurizio, Castiglioni, Battistina, Fabbiocchi, Franco, Onofri, Marco, Lauria, Giulia, De Cesare, Nicoletta, Sangiorgi, Giuseppe, Lettieri, Corrado, Belli, Guido, Poletti, Fabrizio, Pirelli, Salvatore, Klugman, Silvio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Identification of high-risk patients with ST-segment elevation acute myocardial infarction (STEMI) is of the utmost importance for adequate patient stratification and evaluation of additive treatments. However, there is no consensus on the optimal definition of high-risk patients. Methods We therefore compared 5 scoring systems in the assessment of the risk of 30-day mortality in 3214 patients with STEMI treated with primary percutaneous coronary intervention (PCI). Results Clinical scores showed a large variability in risk stratifying patients. Identification of high-risk patients ranged from 15% (PAMI score ≥ 9) to 66% (McNamara definition). McNamara, Antoniucci and Brodie definitions had the best sensitivity (0.87–0.88 and 95% confidence intervals (CI) ranging from 0.82–0.93) while PAMI ≥ 9 had the best specificity (0.87 with 95% CI of 0.86–0.88), while its sensitivity was quite low (0.42). In a sample size simulation of a trial aimed at demonstrating a 33% difference in 30-day mortality between two hypothetical treatments, the number of STEMI patients needed to be screened varied from 4712 for the Brodie definition to 9038 for the PAMI ≥ 9 score. Conclusions There is a large variability in risk stratification, sensitivity, specificity and predictive values among different scoring systems. These considerations should be taken into account when designing randomised trials.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2010.12.007